The method of obtaining pills slow release

 

(57) Abstract:

Usage: in veterinary medicine, in particular in the way of getting of pills for ruminants to combat nematodes, endo - and ectoparasites. The inventive method provides for mixing of the component in a certain ratio, wt. % active ingredient - LL-F-28249-alpha, 23-(o-methyloxime) LL-F-28249-alpha or their derivatives 0,34 - 0,48; lipid component, Carnauba wax 3,6 - 3,96; glycerol - monostearate 14.4V - 15,05; the filler is barium sulfate or baryta detail 77,1 - 80,337. The process is conducted in the mixer at 80C for 10 min, followed by molding the mixture injection molding method using three-stage temperature regime: phase cooled feed-50-60C, the high-temperature phase transition - 100-110C, phase cooled dosage-50-60C. 10 table.

The invention relates to compositions pills containing a prophylactically effective amount of the compound LL-F28249 , 23-(0-methyloxime) LL-F28249, or derivatives thereof, to introduce them to the ruminant animal for the prevention or destruction of nematodes, endoparasites, ectoparasites or acaricide infection in these animals over a long period of time.

P R I m e R 1. Preparation Ino is Trosa 1.0 Dextrin 2,0 Yeast extract 0.5 to Amin 0.5 calcium Carbonate is 0.1 Water To 100 (g)

This medium is sterilized (100 ml), part of this sterile medium in the flask inoculated with mycelial scrapings of the drug on agar Streptomyces cyaneogrisens nencyanogenus NRRL 15773. Then the medium was vigorously stirred in a rotating vibrator within 48-72 h at 28oC, providing primary inoculant. This primary inoculant used for inoculation of 1 l specified sterile environment, which is then grown aerobically at 28oC for 48 h, providing secondary inoculant.

P R I m m e R 2. The fermentation.

Fermentation medium obtained from such a composition, %: Dextrin 1,0 Soy peptone 1.0 Melessa 2.0 calcium Carbonate is 0.1 Water To 100 (g)

This medium is sterilized and then (30 ml) part inoculant 1 l secondary inoculant obtained in example 1. The fermentation is carried out at 30oC when the flow of sterile air 30 l/min, back pressure 8 psig and stirring with a stirrer at 500 rpm, min for 91 hours, removing at this time, the stirrer.

P R I m e R 3. Allocation LL - 28249 .

26 l removed all of fodder obtained in example 2 is mixed with 1500 g of diatomaceous earth and filtered. Mislevy layer was washed with 5 l of water and the filtrate washed, removed. Received miceliului cake mixed with 10 l of methanol in ticengo residue 1-2 HP This aqueous residue is mixed with a double volume of methylene chloride and stirred for 30 minutes Phase methylene chloride is isolated and then concentrated to a syrup, receiving 37 g of crude substance.

These 27 g of crude substance dissolved in a mixture of methylene chloride and methanol, filtered through cotton wool and anhydrous sodium sulphate and then evaporated, receiving 7 g of oil. 170 g (part) of the silica gel was suspended in 12.5% ethyl acetate in methylene chloride and poured for education column 2.5 x 58 see, This oil is dissolved in 12.5% ethyl acetate in methylene chloride and applied to a column. This column elute the same mixture of solvents. Initially, the mobile phase is distilled at 1.3 ml/min and collected in 15-minute fractions. In 10 fractions consumption is reduced to 0.5 ml/min, so that fractions 1-10 have 20 ml of uniformly decreasing to 10 ml, and faction 11-98 contained about 7 ml fractions 99 consumption increased to obtain 25 ml fractions after 10 minutes These fractions were examined by thin-layer chromatography (TLC) in a mixture of ethyl acetate: methylene chloride (1:1).

Faction 55-62 combined and boiled away, receiving 150 mg of a solid product containing LL-F28249 .

150 g of this solid substance containing LL-F-28249 and chromatographically preparative Ehud using to the AI.

Faction 58-69 are combined, the methanol evaporates, add tert-butanol and the mixture lyophilizer, receiving 60 mg of pure LL-F28249 .

This connection can be represented by the following formula

< / BR>
P R I m e R 4. 5-0-tert-butyldimethylsilyl-LL-F28249 .

In 500 ml of CH2Cl270 and LL-F28249 mixed with 82,04 g of imidazole at 20oC under nitrogen. Then within 5 min added 43 g of tert-butyldimethylsilyloxy in 400 ml of CH2Cl2. After one hour the reaction is checked for completion using Ehud using 50% of CH3C, 11-50% H2O mode curved gradient for 10 min on column quick analysis Whatman partisil CCS/C8at a flow rate of 1 ml/min was Added 3 g of tert-butyldimethylsilyloxy and after 3 h the composition is 92.3% of the product of 0.3% LL-F28249 and 1.16% of distilled substances. The mixture was diluted with CH2CL2and poured into 2 l of H2O. the Layer of CH2Cl2singled out. The aqueous portion was extracted with 2 l of CH2CL2and the combined organic layers were obezbedili (Na2SO4) .CH2Cl2boiled away in the vacuum and got 166 g of target compound, which was identified by mass spectrometry and NMR spectrometry.

P R I m e R 5. 5-0-tert-butyldimethylsilyl-23-OC and when the 22oC added 540 g NaOAc, then added 172,5 g pyridylamine (PQQ). After 1 h was added 15 g of PQQ as reaction analysis Ehud not completed. After 2 h was added 10 g of the reaction mixture was stirred in just 5 hours the mixture was poured into 6 l of a mixture of ice water and was isolated CH2CL2. The aqueous layer was extracted with CH2Cl2and merged layers CH2Cl2washed with water and obezvozhivani (Na2SO4).CH2Cl2boiled away in the vacuum and got 197,8 g crude product, which was dissolved in 2 l Et2O and filtered. A solution of Et2O was washed with water (2 x x10000 ml), obezbedili (Na2SO), was evaporated to dryness and received 60 g of target compound, which is identified by mass spectrometry and NMR spectrometry.

Pyridineboronic, replaced by pyridinylamino in this procedure also allows to obtain the target compound.

P R I m e R 6. 23-oxo-LL-F28249 .

1.5 l Meon heating was dissolved 60 g of 5-0-tert-butyldimethylsilyl-23-oxo-LL-F28249 and at 0oC was added 30 g of n-toluene-sulfonic 300 ml Meon. This mixture was stirred 3 h and poured into 6 l of a saturated solution of NaHCO36 l H2O. After mixing, the mixture was extracted with 4 l tOAc and layers vydelennyi with other extracts tOAc, he obezbedili (Na2SO4), tOAc boiled away in the vacuum and got 148,1 g of a dark residue. This crude substance after this has chromatographically EHUD 1200 g SiO2using elution 10 isopropanol in CH2Cl2and monitored by UV detector at 254 nm filter. Faction 39-42 combined, boiled away to dryness and got 12,65 g of target compound, which analyzed the following data:

calculated for C36H50O8:C 70,79; N 8,25.

found: C 60,33; N 8,31.

This is the target connection is additionally determined by means of mass spectrometry and NMR spectrometry.

P R I m e R 7. 23-0-methyloxime-LL-F28249 .

In 930 ml of dry dioxane at room temperature was added 70 g of 23-oxo-LL-F28249 , and 11.8 g of NaOAC, and 11.8 g of CH3ONH2HCl and 2 ml of the SPLA. The mixture was stirred under nitrogen for 3 days and after an absence of source materials according to Ehud 650 ml of dioxane is boiled away in a vacuum. The residue was poured into 5 l of H2O and the product was extracted with CH2Cl2(4 x 2 l). The combined extracts were washed H2O, obezbedili (Na2SO4and boiled away to dryness, the residue was dissolved in 1500 ml of E t2O2the solution was washed with water. Got 11,84 g of target compound, which was identified m the 37H53O8: C 66,64; N 8,46, 2,10

found: C 66,82; N 8,13, 2,32.

This connection can be represented by the following formula

< / BR>
P R I m e R 8. Getting pills for long periods.

The pills contain, %:

23-(0-methyloxime) LL-F28249 (89% real substance) 0.34 Glycerylmonostearate 15,95 Carnauba wax 3,96 Barite 79,75

The monostearate and Carnauba wax are mixed, melted and heated to 105 5oC. To this melt is added the active ingredient and mix until a homogeneous suspension. With continuous stirring to this suspension add barite. Mixing continues until you get a smooth creamy mass. The resulting composition was poured into the form, cooled to room temperature and removed from the mold. The mass of the obtained pills - 51-53, the Pill is rounded at both ends and has dimensions of: thickness 3/4 in, width 7/8 inch, a length of 3.0 inches.

Technical data on glycerylmonostearate show that this substance should be white powder or balls, free from impurities. The particle size should not exceed 5% of the standard sieve No. 20 U.S. and particles are characterized by an acid number of 2-3 and a moisture content of not more than 1.5%. The total content of monoglycerides should Discom without impurities. 100% wax must pass through a standard sieve # 80 US. Acid number of the wax should be 2-6 acetone-soluble resinous ingredient in the 15oC should not exceed 5.0 percent.

Barite should be gray powder without impurities with a bulk density of 150 pounds per cubic foot. The particle size should be such that on a standard sieve N 200 U.S. remained no more than 4% and not less than 80% and passed through a standard sieve of 325 N the United States. Chemical analysis for an acceptable product is BASO490-84%, SiO27-8% and Fe2O30.1 to 0.2%. The density of pills according to the present invention should be between 2.35 and 2,6 0,6.

Other pilule the compositions have a similar way. They are summarized in table.1.

P R I m e R 9. The determination of the speed of destruction of the pills of the present invention.

The rate of release of medication to pills, marked a, b and C in table. 1, are defined first break these pills for compounds 23-(0-methyloxime) LL-F28249 which must be entered calves selected for this test. These samples show that the pill, which must be assessed, contain 0,713, 1035 or 1260 mg 23-(0-methyloxime)-LL-F28249 , 50-53 g pills break in half, weighed and orally administered 0.5 pill each tion the procedures to livestock production. Diet for all animals is a standard ration for cattle.

At intervals through 60, 119 and 167 days after the administration of four animals from each treated group kill, pills extract and study to determine the nature of the surface and then weighed. Results are then recorded and evaluated. The procedure is repeated through 119 days after treatment for the second group of animals from each treatment group and then repeated after 167 days for the third group of animals from each treatment group.

For convenience, the results obtained from each treatment group (four calves in the group), averaged and presented in table.2.

P R I m e R 10. The preparation of pills extended release and evaluation to combat gastrointestinal worms and mites in cattle.

Drugs pills for prolonged release containing mostly 23-(0-methyloxime) LL-F28249 gLite - Almonaster, Carnauba wax and barite, is produced by mixing the appropriate quantity of each substance in the mixer at 80oC for 10 minutes After mixing, the mixture is discharged and sent to the granulator-extruder and/or directly discharged into the injection press.

If conducting the t portion of the cooled feed (50-60oC) part of the high-temperature transition (100-110oC) and part of the cooled dose (50-60oC) flow matrix 1/8 inch, equipped with preryvatelei plate 20 mesh. The temperature of the matrix support 55-60oC. the resulting elongated harness cooled air (air flow is directed into the hole of the matrix) and cut using a hot windshield cutter, granules length of 1/4 inch.

In the case of direct supply of dry mix you can use the delivery system, such as Vibra Screen to submit the matter to the system of injection molding, using a system of heated summer and closing of the nozzle. Working conditions for injection molding should include the temperature profile of the bell shape for granulation, for example the filling 10-20 c, the casting time of 10-20 s, the pressure casting of 0.5 tons per square inch, and the exposure time of 5-10 s, get pills weight 51 grams each, density 2.5 g/MSM3and hardness DELAMAR 77-80 kg

Painkiller obtained by this method are shown in table.3.

The compositions pills, produced by molding under pressure.

To assess videopreteen compositions for combating gastrointestinal worms and tick infestations of cattle ol the La evaluation described pills and marked 1, I, K, and l

Pills contain 0,713, 1035, and 1260 mg 23-(0-methyloxime) LL-F28249 respectively 0.5 pills, each of which weighs 25g

During the week before treatment on the calves spent two separate differential counting nematode eggs and assessed the intensity of tick infestations. Animals were branded on the ear, weighed and assigned to one of four treatment groups (12 calves in each group). The fifth group of 4 animals was also branded on the ear and weighed. This group used to study the feasibility of reintroduction pills, extracted after autopsy other animals.

Differential counts of eggs of nematodes spend a week, two weeks, 1 month, and monthly for 5 months lived before is no longer adequate of a struggle.

The data obtained are given in table.4 and 5, where it can be seen that the control animals not treated within the first 67 days experience, remain heavily infected during this period of experience. Then these animals are treated with levamisole and nematode infestation significantly reduced. Animals receiving the pills of the present invention containing 713-1260 mg 23-(0-methyloxime) LL-F28249 essentially have no nematode infestation after 28-167 days of processing.

P R I m e R 11. Assessment pills with prolonged release of the drug for prevention of psoroptes in cattle.

Pills containing 375 mg of 23-(0-methyloxime) LL-F28249 1/2 pill, obtained by the method of injection molding as described in example 10. These pills had the following composition. Ingredient wt.% g

23-(0-methyloxime)-LL - F28249 1,61 1,53

Glycerol monostearate 15,73 16,52 Carnauba wax 3,93 4,12 Barite unchanged at 78.81 82,75

100,00 105,00

The experimental animal was given half of a 50 mg pill, containing 750 mg of 23-(0-methyloxime) LL-F28249 .

To experience selected mixed heifers. Animals were placed on dry ground, and was with them all the measures for protection against common diseases. They were bonierbale with earrings and put them in boxes to prevent the infestation of scabies. Then for each animal is patnoe animal. Of the animals that are not placed in the barn, picked randomly four uninfected animals. Then these animals were given pills of the present invention and infected them through the week. These animals put ticks (each) six times in the next two weeks.

Were taken precautions to ensure that animals are not infected from each other. The scrapings were made through each week and were studied in the same day.

The number of mites was counted by using a microscope, giving a 20-30-fold increase. Pills weight 375 mg prevented infection with sporoplasm animals undergoing six control infection.

The data obtained are shown below in table.6.

P R I m e R 12. Evaluation of pills containing 23-(0-methyloxime) LL-A to treat head lice and fly the fall in cattle.

Pills tested in this experiment, obtained by the method of injection molding as described in example 10. Received pills have the composition shown in table.7.

For the experiment pills bisected. The pill I contains 375 mg of the active ingredient on half pills. Doom II contains 750 mg aktivnogo> Before the beginning of the experiment all animals were weighed, marked and checked for the presence of lice. The number of lice was determined visually 2-3 devices in the field of ear, eyes, muzzle, paste, dewlap, shoulder blades, spine, the root of the tail and thighs. Animals were randomly allocated into groups: three experimental and one control for 5 animals in each. Groups I, II,III were given pills containing experimental connection, while the control group did not receive pills. All animals were placed on platforms in 2 acres and gave them hay tree Lucerne and mineral feed Supplement. Animals were examined for the presence of lice on 7, 14, 28 day and every two months during the tests. Counting the number of lice were, when the animal was fixed behind the head and under artificial lighting.

Samples of faeces were taken (approximately 10 g) for screening for the presence of nematodes on 7, 14, 28 day, and a month after that. These samples were stored at -10oC..

All groups treated with pills (375 mg, 750 mg and 1125 mg), had a small number of lice Solenoptes capillatus within a week after treatment. The complete destruction of lice Solenoptes capillatus in all animals treated with pills, was achieved in 100 days.

P R I m e p 13. Ozokerit time.

Used in this experiment pills received by infectious molding as described in example 10. Pills had the following composition. Ingredient wt. g

23-(0-methyloxime) LL-F28249 1,6 3,2

Glycerol monostearate 14,4 28,8

Carnauba wax 3,6 7,2 Barite 80,4 160,8

100,0 200,0

In these experiments, mixed purebred animals naturally infected Hypoderma Spp., the first stages are randomly divided into groups of 4 animals each. One group was left as control and the other group received half 50-54 g pills containing 375 mg of 23-(0-methyloxime) LL-F28249 . On Palilula gave calving animals with the help of bloodwater.

After that, the efficacy of the drug was determined by visual inspection and palpation of the sides of the animal through the week to identify the presence of nodules. Drug treatment 23-(0-methyloxime) LL-F28249 in the pills was fully effective against Hpoderma spp. On the flanks of the animals treated with pills, 375 mg of the indicated drug for 72 days, not detected larvae, however, the control group had an average of 12 (range 4-19) larvae/head and peak on day 58 and 8.8 - 72-day.

P R I m e R 14. Evaluation of pills, the The pill has received is as follows.

The monostearate and Carnauba wax were mixed, melted and heated up to 1055oC. To this mixture was added the active ingredient and mixed the mixture until a homogeneous suspension. To this suspension was added barite with constant stirring. Mixing continued until a homogeneous mixture has a creamy consistency. The resulting mixture is poured into the form, allowed to cool to room temperature and unloaded from the mold. Received pills weighed 51-53, Pills with both ends have a domed shape and 3/4 inch thickness. 7/8 inches wide and 3.0 inches in length.

Half the pills were given a weight of 25.5-27,0 g) animals on pasture. The drug efficacy was observed within 120 days by determining the number of internal and external parasites.

Pill 1 contains 75 mg of LL-F28249 half pill, the pill II 375 mg of LL-F28249 half pill, the pill III - 1875 mg of LL-F28249 half pills.

In this experiment the animals to pasture randomly divided into groups of 5 animals in each group and mark it. Before the experiment animal faeces were examined in order to determine the average number of eggs of nematodes per gram of faeces in laboratory animals. All animals was the presence of 2700-3000 eggs per 1 g of faeces. Ispytaniye 3.75 mg/kg body weight of levamisole in the beginning of the test and 62 day; other groups got half pill I, II or III, which contained 75, 375 or 1875 LL-28249, respectively (see tab.8). Then the animals were placed in individual stalls and examined them during the period of detention for 120 days. 7, 16, 32, 62, 91 and 106 weeks after taking the pill were collected from each animal faeces and determined the number of eggs of nematodes per gram of faeces. The data obtained show that pill with a content of 75 mg of active ingredient reduces the eggs of nematodes and nematodes below, which was obtained after two treatment with levamisole. 375 and 1875 mg pills give to 99.9% reduction in the number of eggs of nematodes during the first week and kill 99.9% of nematodes (see tab. 9). Additional gain in animals treated with 275 and 1875 mg pills, were highly statistically significant. The weight of animals treated with 75 mg pills, was equal to the weight of animals treated with levamisole (see tab.10).

The METHOD of OBTAINING PILLS EXTENDED RELEASE for oral administration of the ruminant animal, comprising mixing the active ingredient, the lipid component and the filler by heating, followed by molding the mixture, characterized in that the active ingredient used LL - F - 28249 , 23-(O-methyloxime) L is the firmness of the filler - barium sulfate or Britney detail in the following ratio, wt.%:

LL - F - 28249 , 23-(O-methyloxime)LL - F - 28249 or their derivatives 0,34 - 0,84

Glycerol-monostearate 14,40 - 15,95

Carnauba wax 3,60 - 3,96

Barium sulfate or barium detail 77,10 - 80,337

all components are mixed in the mixer at 80oC for 10 min, and the molding mixture is performed with injection molding method using three-stage temperature range: phase cooled feed - 50 - 60oWith the high-temperature phase transition - 100 - 110oWith the phase cooled dosage - 50 - 60oC.

 

Same patents:
The invention relates to medicine and can be used in clinical medicine to treat wounds, burns, cuts, etc

The invention relates to biotechnology and concerns a method for obtaining liposomes containing water-soluble low-molecular compounds

The invention relates to medicine, namely to physiotherapy, and touches the contact environment, used for phonophoresis of various diseases

The invention relates to medicine, namely to ophthalmology products used as ophthalmic preparation containing a water-soluble vitamin in a mixture of drug and excipients involved in carbohydrate, protein and fat metabolism and maintain normal visual function of the eye

The invention relates to the medical industry, namely the production of drugs, in particular, mustard

The invention relates to medicine, namely, pharmaceutical preparations for oral administration, mainly in pediatric practice

The invention relates to pharmaceutical industry and relates to a method of obtaining capsules etoposide

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes new tablets with size less 3 mm with sustained-releasing the opioid analgesic drug for 30 min in the amount above 75%. Invention provides opioid for oral intake with taking into account individual necessity of patient due to selection of required amount of mictotablets by dispenser.

EFFECT: valuable properties of tablet, expanded assortment of medicinal formulations of opioid analgesics.

19 cl, 4 tbl, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes new tablets with size less 3 mm with sustained-releasing the opioid analgesic drug for 30 min in the amount above 75%. Invention provides opioid for oral intake with taking into account individual necessity of patient due to selection of required amount of mictotablets by dispenser.

EFFECT: valuable properties of tablet, expanded assortment of medicinal formulations of opioid analgesics.

19 cl, 4 tbl, 4 ex

FIELD: pharmacy.

SUBSTANCE: invention relates to pharmaceutical compositions in the form of cellular mechanically stable, lamellar, porous, spongy or foam-like structures and to a method for their preparing from solutions and dispersions. Method involves carrying out the following stages: a) preparing a solution or homogenous dispersion liquid and compound taken among the group including one or some pharmaceutically active compounds, one or some pharmaceutically acceptable additives and their mixtures, and the following stage b) foaming solution or homogenous dispersion at reducing pressure 30-150 torrs without boiling. Invention provides stabilizing the composition.

EFFECT: improved preparing method.

38 cl, 4 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a tablet decomposing rapidly in the buccal pocket and comprising a medicinal agent, excipient and saccharide with relatively lower melting point than that of a medicinal agent and excipient. Tablet is made by uniform mixing saccharide with low melting point with tablet mass to form bridge between particles of named medicinal agent and/or excipient through melting product followed by hardening mentioned saccharide with low melting point. Except for, invention relates to a method for making tablet decomposing rapidly in buccal pocket and comprising a medicinal agent, excipient and saccharide with relatively lower melting point than that of medicinal agent and excipient. Method involves: (a) the parent components of tablet comprising a medicinal agent, excipient and saccharide with relatively lower melting point that that of a medicinal agent and excipient are pressed under low pressure to provide the required tablet form; (b) pressed product obtained after stage (a) is heated to temperature when saccharide with low melting point is melted; (c) melted product obtained after stage (b) is cooled to temperature when melted saccharide with low melting point is hardened. Invention represents a tablet decomposing rapidly in buccal pocket and having the tablet strength providing its using in tablet-making machines for dosed formulations and giving the possibility for making tablet using common tablet-making machines, and to a method for making tablets. Except for, invention represents a tablet decomposing rapidly in buccal pocket being this table as compared with common tablets has enhanced tablet strength and improved frangibility without prolonged decomposing time in buccal pocket, and a method for tablet making.

EFFECT: improved making method.

63 cl, 4 tbl, 1 dwg, 21 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes sterile anesthetic composition for parenteral administration of propofol emulsified in water for injection. The composition comprise above 3 wt.-% but 6 wt.-% of less of solvent not mixing with water. Propofol is dissolved in indicated solvent. The composition is stabilized with 0.2-1.0 wt.-% of surface-active substance and has pH value level in the range 5.0-7.5. The composition with reduced pH value level allows preventing above 10-fold elevating growth of microorganisms for at least 24 h after random external pollution. Reduced fat content in composition also provides the stable analgetic effect for prolonged time and with reduced risk for the blood fat content exceeding.

EFFECT: improved and valuable properties of composition.

15 cl, 4 dwg, 4 tbl, 3 ex

FIELD: medicine, hematology, pharmacy.

SUBSTANCE: invention relates to the composition of factor VIII composed without addition of albumin and comprising the following excipients of composition in addition to factor VIII: from 4% to 10% of filling agent taken among group consisting of mannitol, glycine and alanine; from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose, arginine; from 1 mM to 5 mM of calcium salt, from 100 mM to 300 mM of NaCl, and buffer agent for pH value maintenance about between 6 and 8. Alternatively, the composition can comprise from 2% to 6% of hydroxyethylstarch; from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose, arginine; from 1 mM to 5 mM of calcium salt, from 100 mM to 300 mM of NaCl, and buffer agent for pH value maintenance between 6 and 8. In additional variant of realization of invention the composition can comprise: from 300 mM to 500 mM of NaCl, from 1% to 4% of stabilizing agent taken among group consisting of sucrose, trehalose, raffinose and arginine; from 1 mM to 5 mM of calcium salt, and buffer agent. The composition provides stability in the absence of albumin or other proteins.

EFFECT: valuable properties of compositions.

35 cl, 11 tbl, 7 ex

FIELD: biotechnology, veterinary medicine.

SUBSTANCE: invention relates to the development of biological preparation for prophylaxis and treatment of colibacillosis (escherichiosis) and for control of carriage of escherichious infections pathogens in animals and poultries also. Also, invention can be used in producing curative fodders and ecologically pure human foodstuffs. Biopreparation for prophylaxis and treatment of escherichiosis in animals and poultries comprises strains of bacteriophages Phagum Escherichia coli Ec022-DEP and/or Phagum Escherichia coli Ec021-DEP, and/or Phagum Escherichia coli Ex0782-DEP, and/or Phagum Escherichia coli Ec0781-DEP, and/or Phagum Escherichia coli EPZ-1-DEP, and/or Phagum Escherichia coli EPZ-2-DEP, and/or Phagum Escherichia coli EG-5-DEP, and/or Phagum Escherichia coli BC-1-DEP, and/or Phagum Escherichia coli M78-DEP, and/or Phagum Escherichia coli Sheksna 2k-DEP taken in the effective amount. The biopreparation comprises also antiseptic, for example, quinosol and a stabilizing agent. Protein (for example, soybean protein), vegetable meal, organic polymer, milk, serum, albumin can be used as a stabilizing agent. Among organic polymers can be used: dextran, polyglucin, starch, polyvinylpyrrolidone. The biopreparation can be dried by lyophilization, granulated and placed in polymeric matrix. The biopreparation has no toxic properties on animals, it shows good hygroscopicity and can be good dispersed in water. The biopreparation can be used in liquid and dry prescription formulations and in different methods of its administrations: both by subcutaneous, intraperitoneal, intramuscular injections and as an aerosol, by administration of phage particles into lung compartments including applying as curative fodder and supplement to fodder, and by applying on surface of cutaneous integuments. Invention provides enhancing the effectiveness of treatment of animals and poultries with gastroenteric infections due to reducing treatment period, expanding spectrum of lytic effect of the biopreparation, resistance to effect of digestive tract enzymes and convenience in using.

EFFECT: valuable veterinary properties of biopreparation.

9 cl, 5 tbl, 7 ex

FIELD: biotechnology, veterinary medicine.

SUBSTANCE: invention relates to the development of biological preparation for prophylaxis and treatment of colibacillosis (escherichiosis) and for control of carriage of escherichious infections pathogens in animals and poultries also. Also, invention can be used in producing curative fodders and ecologically pure human foodstuffs. Biopreparation for prophylaxis and treatment of escherichiosis in animals and poultries comprises strains of bacteriophages Phagum Escherichia coli Ec022-DEP and/or Phagum Escherichia coli Ec021-DEP, and/or Phagum Escherichia coli Ex0782-DEP, and/or Phagum Escherichia coli Ec0781-DEP, and/or Phagum Escherichia coli EPZ-1-DEP, and/or Phagum Escherichia coli EPZ-2-DEP, and/or Phagum Escherichia coli EG-5-DEP, and/or Phagum Escherichia coli BC-1-DEP, and/or Phagum Escherichia coli M78-DEP, and/or Phagum Escherichia coli Sheksna 2k-DEP taken in the effective amount. The biopreparation comprises also antiseptic, for example, quinosol and a stabilizing agent. Protein (for example, soybean protein), vegetable meal, organic polymer, milk, serum, albumin can be used as a stabilizing agent. Among organic polymers can be used: dextran, polyglucin, starch, polyvinylpyrrolidone. The biopreparation can be dried by lyophilization, granulated and placed in polymeric matrix. The biopreparation has no toxic properties on animals, it shows good hygroscopicity and can be good dispersed in water. The biopreparation can be used in liquid and dry prescription formulations and in different methods of its administrations: both by subcutaneous, intraperitoneal, intramuscular injections and as an aerosol, by administration of phage particles into lung compartments including applying as curative fodder and supplement to fodder, and by applying on surface of cutaneous integuments. Invention provides enhancing the effectiveness of treatment of animals and poultries with gastroenteric infections due to reducing treatment period, expanding spectrum of lytic effect of the biopreparation, resistance to effect of digestive tract enzymes and convenience in using.

EFFECT: valuable veterinary properties of biopreparation.

9 cl, 5 tbl, 7 ex

FIELD: agriculture, animal husbandry, organic chemistry.

SUBSTANCE: antiseptic ointment comprises cationic surface-active substance, lower glycols, polyethylene glycols, water and ethylene glycol monophenolic ester and higher polyethylene glycols taken in the definite ratio of components. As cationic surface-active substance ointment comprises N-alkyl-N-alkoxycarbonylmethylhexahydroazipinium chloride or alkyldimethylbenzylammonium chloride, or cetylpyridinium bromide, or cetylpyridinium chloride, or 1,2-ethylenebis-(N-methylcarbdecyloxymethyl)ammonium dichloride, or ethylhexadecyldimethylammonium chloride, or chlorhexidine; as lower glycol ointment comprises 1,2-propylene glycol or polyethylene glycol-300, or polyethylene glycol-400; as higher polyethylene glycol ointment comprises polyethylene glycol-1500 or polyethylene glycol-3000, or polyethylene glycol-4000, or polyethylene glycol-6000. Ointment elicits the high antibacterial activity, broad spectrum of bactericidal effect and low irritating effect with respect to udder skin. Invention can be used for sanitary-hygienic treatment of udder of lactating cows for prophylaxis and rapid healing external damages of udder and nipples (arising cracks), prophylaxis of mastitis, enhancing milk purity by microbiological indices.

EFFECT: valuable antiseptic properties of ointment.

2 cl, 1 tbl, 22 ex

FIELD: pharmacology, fluorinated quinolone-based drug, in particular ofloxacine for injections.

SUBSTANCE: claimed composition contains therapeutically acceptable amount of ofloxacine and trilon-B, sodium chloride, water for injections as additives.

EFFECT: high therapeutic effectiveness; non-crystallized active agent for a long-time storage.

1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes new tablets with size less 3 mm with sustained-releasing the opioid analgesic drug for 30 min in the amount above 75%. Invention provides opioid for oral intake with taking into account individual necessity of patient due to selection of required amount of mictotablets by dispenser.

EFFECT: valuable properties of tablet, expanded assortment of medicinal formulations of opioid analgesics.

19 cl, 4 tbl, 4 ex

Up!